The Effects of Post-Conditioning and Administration of Vitamin C on Intramuscular High Energy Phosphate Levels
NCT ID: NCT00534924
Last Updated: 2007-09-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
INTERVENTIONAL
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Therapies are required which can be administered after the onset of an ischemic event to protect the tissue against IR injury. Therefore, a promising strategy to reduce IR injury is post-conditioning.
Likewise, pharmacological therapies administered after the onset of reperfusion might prevent tissue injury. We have recently shown that high concentrations of exogenous vitamin C abrogate experimental IR injury of the forearm vasculature in patients with peripheral artery disease and in healthy subjects.
Study hypothesis
We hypothesize that the administration of mechanical post-conditioning or of high-dose vitamin C may protect skeletal muscle against IR injury. This shall be studied employing MR spectroscopy of the leg, which is an established model to assess muscle aerobic energy metabolism.
Design
Three periods, three way cross over study in 10 volunteers. One screening visit, three one-day study days with two washout periods of \>3 days in between are scheduled for each participant. The order of experimental days will be randomized. After the last treatment a final follow-up examination will be performed within one week.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
No intervention after IR injury
no intervention
2
Postconditioning
Postconditioning
3
Vit. C
Vit C
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vit C
Postconditioning
no intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Nonsmoker for more than 3 months
* Body mass index between 18 and 25 kg/m2
* Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
Exclusion Criteria
* Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
* Evidence of hypertension, pathologic hyperglycemia, hyperlipidemia
* Treatment in the previous 3 weeks with any drug including over-the-counter drugs.
* Symptoms of a clinically relevant illness in the 2 weeks before the first study day
* History or presence of gastrointestinal, liver of kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of the study drug
* Blood donation during the previous 3 weeks
* History of hypersensitivity to parenteral vitamin C.
* Glucose-6-phosphate dehydrogenase deficiency
* Thalassemia, haemochromatosis
* History of urolithiasis
* Any metallic or paramagnetic device not removable
* Claustrophobia
* Regular use of supplementary oral Vitamin C or Vitamin C containing substances
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Wolzt, MD, Prof.
Role: PRINCIPAL_INVESTIGATOR
Head of research group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Martin Andreas, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT: 2007-002520-16
Identifier Type: -
Identifier Source: org_study_id